Home
Mercati
Grafici & Idee
Algo
Notizie
Store
Broker
Scarica
Calendario Economico
Segnali di Trading
Terminale Web
Digita
/
per cercare: @user, $symbol
Cerca
Accedi
Crea un account
Italiano
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Türkçe
OKYO
#6046
OKYO Pharma Limited Ordinary Shares
1.7
1
0.00%
Settore:
Base:
Valuta di Profitto:
Intervallo Giornaliero
Intervallo Annuale
Variazione giornaliera
0.00%
Variazione Mensile
-23.32%
Variazione di 6 mesi
-24.67%
Variazione Annuale
+44.92%
Chiusura Precedente
1.7
1
Open
1.7
1
Bid
Ask
Low
1.7
1
High
1.7
1
Volume
2
Mercati
Mercato Azionario Statunitense
Salute
OKYO
Open full chart
Financials
Overview
Estratto Conto
Statistics
Dividends
Quarterly
Annual
Value
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
1.37 B
25.55 M
33.84 M
37.61 M
—
Valuation ratios
Enterprise value
—
—
48.91 M
43.17 M
—
Price to earnings ratio
—
—
—
—
—
Price to sales ratio
—
—
—
—
—
Price to cash flow ratio
—
—
—
—
—
Price to book ratio
—
—
—
—
—
Enterprise value to EBITDA ratio
—
—
—
—
—
Profitability ratios
Return on assets %
-1.26
2.56
10.9
1.28
—
Return on equity %
-1.84
-6.48
-2.86
-0.85
—
Return on invested capital %
—
—
—
—
—
Gross margin %
—
—
—
100
—
Operating margin %
—
—
—
-38.54 K
—
EBITDA margin %
—
—
—
—
—
Net margin %
—
—
—
85.88 K
—
Liquidity ratios
Quick ratio
—
—
—
—
—
Current ratio
3.17
0.72
0.21
0.4
—
Inventory turnover
—
—
—
—
—
Asset turnover
0
0
0
0
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
—
—
—
EBIT per share
—
—
—
—
—
EBITDA per share
—
—
—
—
—
Total debt per share
—
—
—
—
—
Cash per share
—
—
—
—
—
Net current asset value per share
—
—
—
—
—
Tangible book value per share
—
—
—
—
—
Working capital per share
—
—
—
—
—
Book value per share
—
—
—
—
—
Notizie
Piper Sandler avvia la copertura su OKYO Pharma con rating Overweight
Piper Sandler initiates OKYO Pharma stock with Overweight rating
Il titolo di OKYO Pharma crolla dopo l’annuncio di un’offerta pubblica da 20 milioni
OKYO Pharma stock tumbles on $20 million public offering announcement
OKYO Pharma annuncia offerta pubblica di azioni ordinarie per 20 milioni di dollari
OKYO Pharma announces $20 million public offering of ordinary shares
OKYO Pharma trasferisce l’offerta di equity ATM a Leerink Partners come agente di vendita
OKYO Pharma transitions ATM equity offering to Leerink Partners as sales agent
OKYO Pharma appoints former Dompé CMO Flavio Mantelli to lead NCP program
OKYO Pharma presenterà i risultati dello studio su urcosimod per NCP al meeting ASCRS
OKYO Pharma to present urcosimod NCP study results at ASCRS meeting
H.C. Wainwright conferma il rating Buy su OKYO Pharma con target di $7